EUVIMEDEUVIMED entdecken
Crossref

KREMEN2 promotes the proliferation and the metastasis through activating PI3K/AKT/mTOR signaling pathway in non-small cell lung cancer

Shunying Wang iD, Li Li, Wenming Wang

Biochemistry and Cell Biology · 2025

DOI: 10.1139/bcb-2025-0039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemistry and Cell Biology, 2025. Verfasst von Shunying Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cadre Health Section, Jinan City People's Hospital, Jinan, Shandong 271199, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Lung Neoplasms. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our purpose was to explore the role and regulatory mechanisms of kringle containing transmembrane protein 2 (KREMEN2) in the development and progression of non-small cell lung cancer (NSCLC). KREMEN2 expression levels were higher in NSCLC tissues and cells than in normal tissues and cells. Down-regulation of KREMEN2 by siRNAs suppressed proliferation, migration, invasion, and epithelial mesenchymal transition (EMT), and accelerated apoptosis in NSCLC cells. Furthermore, KREMEN2 knockdown repressed PI3K/AKT/mTOR signaling, and KREMEN2 overexpression activated PI3K/AKT/mTOR signaling. Additionally, PI3K activator (740Y-P) treatment or PI3K overexpression reversed the inhibitory function of KREMEN2 knockdown on proliferation and metastasis, as well as the strengthened function of KREMEN2 knockdown on the apoptosis of NSCLC cells. Moreover, KREMEN2 suppressed tumor growth by inhibiting PI3K/AKT/mTOR signaling in mice. The pharmacologic inhibitor of KREMEN2 (genistein) was also demonstrated to suppress tumor growth in mice. In conclusion, our study suggested that KREMEN2 knockdown could repress the proliferative, migratory, and invasive capacity, as well as EMT, while accelerating the apoptotic capacity of NSCLC cells by inhibiting PI3K/AKT/mTOR signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktLung NeoplasmsCell ProliferationPhosphatidylinositol 3-KinasesSignal TransductionMembrane ProteinsHumansAnimalsMiceMice, NudeApoptosisEpithelial-Mesenchymal TransitionMaleCell MovementFemaleMice, Inbred BALB CNeoplasm MetastasisCell Line, Tumor

Stichwörter der Autor:innen

KREMEN2NSCLCPI3K/AKT/mTOR signalingmigrationproliferation

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMTOR protein, humanMembrane Proteins

Autor:innen und Institutionen

  • Department of Cadre Health Section, Jinan City People's Hospital, Jinan, Shandong 271199, P.R. China.
  • Department of Nephrology, Jinan City People's Hospital, Jinan, Shandong 271199, P.R. China.

ORCID-Profile: Shunying Wang

Zitieren

APA

Wang, S., Li, L., & Wang, W. (2025). KREMEN2 promotes the proliferation and the metastasis through activating PI3K/AKT/mTOR signaling pathway in non-small cell lung cancer. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2025-0039

Vancouver

Wang S, Li L, Wang W. KREMEN2 promotes the proliferation and the metastasis through activating PI3K/AKT/mTOR signaling pathway in non-small cell lung cancer. Biochemistry and Cell Biology. 2025. doi:10.1139/bcb-2025-0039

BibTeX
@article{Wang2025,
  author = {Wang, Shunying and Li, Li and Wang, Wenming},
  title = {KREMEN2 promotes the proliferation and the metastasis through activating PI3K/AKT/mTOR signaling pathway in non-small cell lung cancer},
  journal = {Biochemistry and Cell Biology},
  year = {2025},
  doi = {10.1139/bcb-2025-0039}
}
Kostenlos starten →